Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Carolyn Bolden-Watson"'
Autor:
John A. Ascher, Trisha L. Houser, Karen L. Weihs, Carolyn Bolden-Watson, Alan Metz, Sharyn R. Batey, Rafe M. J. Donahue
Publikováno v:
Biological Psychiatry. 51:753-761
This was the first controlled continuation phase study (up to 1-year total treatment) to evaluate the safety and efficacy of bupropion SR for decreasing the risk for relapse of depression in patients who responded to bupropion SR.Patients with recurr
Autor:
Harry A. Croft, Rafe M. J. Donahue, Trisha L. Houser, Brenda D. Jamerson, Robert A. Leadbetter, Alan Metz, Carolyn Bolden-Watson
Publikováno v:
Clinical Therapeutics. 24:662-672
Short-term studies have demonstrated a modest weight-reducing to weight-neutral effect among patients receiving bupropion sustained-release (SR) for the treatment of depression.This study was conducted to evaluate the long-term effects of bupropion S
Autor:
Thomas J. Carmody, T. L. Houser, R. M J Donahue, A. Metz, Madhukar H. Trivedi, A.J. Rush, Carolyn Bolden-Watson
Publikováno v:
Scopus-Elsevier
Objective To examine the effects of bupropion sustained release (SR) and sertraline on anxiety in outpatients with recurrent DSM-IV-defined major depressive disorder. Method This retrospective analysis was conducted using pooled data from 2 identical
Autor:
Thomas J. Carmody, Madhukar H. Trivedi, Alan Metz, A. John Rush, Rafe M. J. Donahue, Carolyn Bolden-Watson, Trisha L. Houser, John A. Ascher, Sharyn R. Batey
Publikováno v:
Neuropsychopharmacology. 25:131-138
Our objective was to determine if pretreatment anxiety levels were associated with preferential response to bupropion sustained release (n = 122) or sertraline (n = 126) during a 16-week randomized acute phase treatment study. Both agents had compara
Autor:
John A. Ascher, Richard Kavoussi, Harry A. Croft, Alan Metz, Sharyn R. Batey, R. Taylor Segraves, Carolyn Bolden-Watson, Vicki J. Foster
Publikováno v:
Journal of Sex & Marital Therapy. 27:303-316
This article describes the results of the first report of bupropion sustained release (SR) in nondepressed females with hypoactive sexual desire disorder (HSDD). Eligible females entered a 4-week, single-blind, placebo baseline phase. Subjects, all o
Publikováno v:
Cephalalgia. 19:668-675
Polypharmacy (the prescription of more than one therapy for a single patient) and subcutaneous (s.c.) sumatriptan tolerability were prospectively studied in 12,339 migraineurs, each followed for up to 1 year. Inclusion/exclusion criteria were minimal
Publikováno v:
Biochemical Pharmacology. 45:2352-2354
Based on molecular cloning studies, five different muscarinic receptor subtypes exist: m1, m2, m3, m4, and m5. We determined the affinity and selectivity of binding for sixteen antidepressants, two of their metabolites, and three antihistaminics (H1)
Autor:
Sharyn R. Batey, M.J. Book, John A. Ascher, B.R. King, Nathalie Richard, Carolyn Bolden-Watson, C.C. Coleman, Brenda D. Jamerson, Alan Metz, R.T. Segraves
Publikováno v:
Clinical therapeutics. 23(7)
Many antidepressants are associated with sexual dysfunction, a side effect that may lead to patients' dissatisfaction and noncompliance with treatment.This study compared the efficacy, tolerability, and effects on sexual functioning of bupropion sust
Autor:
Stuart R. Stark, Stephen O'Quinn, Gayla Putnam, Egilius L.H. Spierings, Scott McNeal, Carolyn Bolden-Watson
Publikováno v:
Headache. 40(7)
Objectives.—To determine whether 347 patients would respond to a 50-mg oral dose of sumatriptan, even though they considered themselves poor responders to this acute therapy for migraine, and to investigate whether oral naratriptan can be an effect
Autor:
Eileen Monaghan, Jing Zhou, John A. Ascher, Charles L. Bowden, Joseph R. Calabrese, John W. Anderson, Linda J. Rhodes, Paul E. Keck, Carolyn Bolden-Watson, Susan L. McElroy, John Cookson
Publikováno v:
Biological psychiatry. 45(8)
Background: Patients with bipolar disorder (BD) who have rapid cycling features are often treatment refractory. Clear and conclusive evidence regarding effective treatments for this group is not available. Methods: Patients with diagnoses of refracto